Piramal Pharma said while the YoY financials are not strictly comparable due to the non-inclusion of certain "non-common control transactions" with the Piramal Enterprises Ltd (PEL), it attributed the drop in EBITDA to higher operating expenses including raw material cost, energy prices, wage inflation, and marketing cost